⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293653 | 0.73 | — | — | |
| SCHEMBL474814 | 0.71 | — | — | |
| SCHEMBL1656918 | 0.71 | — | — | |
| SCHEMBL10739303 | 0.71 | KDM4E (0.43) | — | |
| SCHEMBL13978172 | 0.69 | — | — | |
| SCHEMBL85842 | 0.69 | — | — | |
| SCHEMBL8107 | 0.67 | KDM4E (0.71) | — | |
| SCHEMBL170514 | 0.67 | — | — | |
| SCHEMBL7442539 | 0.67 | — | — | |
| SCHEMBL17188612 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | claimed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | claimed |
| EP-4276198-A2 | NUCLEIC ACID SYNTHESIS AND SEQUENCING USING TETHERED NUCLEOSIDE TRIPHOSPHATES | The Regents of The University of California Santa Cruz (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3825412-B1 | NUCLEIC ACID SYNTHESIS AND SEQUENCING USING TETHERED NUCLEOSIDE TRIPHOSPHATES | UNIV CALIFORNIA (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11732283-B2 | Nucleic acid synthesis and sequencing using tethered nucleoside triphosphates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-22 | — | — | US | disclosed |
| US-11624079-B2 | Polymerase-tethered nucleotides for nucleic acid synthesis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-11 | — | — | US | disclosed |
| CN-114874337-A | Nucleic acid synthesis and sequencing using tethered nucleoside triphosphates | 加利福尼亚大学董事会 | 2022-08-09 | — | — | CN | disclosed |
| US-20220205008-A1 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-30 | — | — | US | disclosed |
| CN-109642255-B | Nucleic acid synthesis and sequencing using tethered nucleoside triphosphates | 加利福尼亚大学董事会 | 2022-06-03 | — | — | CN | disclosed |
| US-11254961-B2 | Polymerase-tethered nucleoside triphosphates for use in nucleic acid synthesis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006109026-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006106306-A1 | PYRIMIDINES AS IGF-I INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006106307-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006100461-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
| EP-1678169-A1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |